Annelies Van Rie1, Aimee Mupuala, Anna Dow. 1. Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina 27599-7435, USA. vanrie@email.unc.edu
Abstract
OBJECTIVES: Pediatric HIV infection is a growing problem in most regions of the world. Data on the effects of HIV on the neurodevelopment of children in resource-poor settings are scarce but necessary to guide interventions. The purpose of this study was to compare the neurodevelopment of preschool-aged HIV-infected, HIV-affected (HIV-uninfected AIDS orphans and HIV-uninfected children whose mother had symptomatic AIDS), and healthy control children in Kinshasa, Democratic Republic of Congo. METHODS: Thirty-five HIV-infected, 35 HIV-affected, and 90 control children aged 18 to 72 months were assessed by using the Bayley Scales of Infant Development II, Peabody Developmental Motor Scales, Snijders-Oomen Nonverbal Intelligence Test, and Rossetti Infant-Toddler Language Scale, as appropriate for age. RESULTS: Overall, 60% of HIV-infected children had severe delay in cognitive function, 29% had severe delay in motor skills, 85% had delays in language expression, and 77% had delays in language comprehension, all significantly higher rates as compared with control children. Young HIV-infected children (aged 18-29 months) performed worse, with 91% and 82% demonstrating severe mental and motor delay, respectively, compared with 46% and 4% in older HIV-infected children (aged 30-72 months). HIV-affected children had significantly more motor and language expression delay than control children. CONCLUSIONS: The impact of the HIV pandemic on children's neurodevelopment extends beyond the direct effect of the HIV virus on the central nervous system. AIDS orphans and HIV-negative children whose mothers had AIDS demonstrated significant delays in their neurodevelopment, although to a lesser degree and in fewer developmental domains than HIV-infected children. Young HIV-infected children were the most severely afflicted group, indicating the need for early interventions. Older children performed better as a result of a "survival effect," with only those children with less aggressive disease surviving.
OBJECTIVES:Pediatric HIV infection is a growing problem in most regions of the world. Data on the effects of HIV on the neurodevelopment of children in resource-poor settings are scarce but necessary to guide interventions. The purpose of this study was to compare the neurodevelopment of preschool-aged HIV-infected, HIV-affected (HIV-uninfected AIDS orphans and HIV-uninfectedchildren whose mother had symptomatic AIDS), and healthy control children in Kinshasa, Democratic Republic of Congo. METHODS: Thirty-five HIV-infected, 35 HIV-affected, and 90 control children aged 18 to 72 months were assessed by using the Bayley Scales of Infant Development II, Peabody Developmental Motor Scales, Snijders-Oomen Nonverbal Intelligence Test, and Rossetti Infant-Toddler Language Scale, as appropriate for age. RESULTS: Overall, 60% of HIV-infectedchildren had severe delay in cognitive function, 29% had severe delay in motor skills, 85% had delays in language expression, and 77% had delays in language comprehension, all significantly higher rates as compared with control children. Young HIV-infectedchildren (aged 18-29 months) performed worse, with 91% and 82% demonstrating severe mental and motor delay, respectively, compared with 46% and 4% in older HIV-infectedchildren (aged 30-72 months). HIV-affectedchildren had significantly more motor and language expression delay than control children. CONCLUSIONS: The impact of the HIV pandemic on children's neurodevelopment extends beyond the direct effect of the HIV virus on the central nervous system. AIDS orphans and HIV-negative children whose mothers had AIDS demonstrated significant delays in their neurodevelopment, although to a lesser degree and in fewer developmental domains than HIV-infectedchildren. Young HIV-infectedchildren were the most severely afflicted group, indicating the need for early interventions. Older children performed better as a result of a "survival effect," with only those children with less aggressive disease surviving.
Authors: T E Taha; S M Graham; N I Kumwenda; R L Broadhead; D R Hoover; D Markakis; L van Der Hoeven; G N Liomba; J D Chiphangwi; P G Miotti Journal: Pediatrics Date: 2000-12 Impact factor: 7.124
Authors: L G Epstein; L R Sharer; J M Oleske; E M Connor; J Goudsmit; L Bagdon; M Robert-Guroff; M R Koenigsberger Journal: Pediatrics Date: 1986-10 Impact factor: 7.124
Authors: A L Belman; M H Ultmann; D Horoupian; B Novick; A J Spiro; A Rubinstein; D Kurtzberg; B Cone-Wesson Journal: Ann Neurol Date: 1985-11 Impact factor: 10.422
Authors: Sophie H Eickmann; Ana C V Lima; Miriam Q Guerra; Marilia C Lima; Pedro I C Lira; Sharon R A Huttly; Ann Ashworth Journal: Dev Med Child Neurol Date: 2003-08 Impact factor: 5.449
Authors: Michael J Boivin; Theodore D Ruel; Hannah E Boal; Paul Bangirana; Huyen Cao; Leigh A Eller; Edwin Charlebois; Diane V Havlir; Moses R Kamya; Jane Achan; Carolyne Akello; Joseph K Wong Journal: AIDS Date: 2010-05-15 Impact factor: 4.177
Authors: Theodore D Ruel; Michael J Boivin; Hannah E Boal; Paul Bangirana; Edwin Charlebois; Diane V Havlir; Philip J Rosenthal; Grant Dorsey; Jane Achan; Carolyne Akello; Moses R Kamya; Joseph K Wong Journal: Clin Infect Dis Date: 2012-02-04 Impact factor: 9.079
Authors: Kevin Robertson; Jeff Liner; James Hakim; Jean-Louis Sankalé; Igor Grant; Scott Letendre; David Clifford; Amadou Gallo Diop; Assan Jaye; Georgette Kanmogne; Alfred Njamnshi; T Dianne Langford; Tufa Gemechu Weyessa; Charles Wood; Mwanza Banda; Mina Hosseinipour; Ned Sacktor; Noeline Nakasuja; Paul Bangirana; Robert Paul; John Joska; Joseph Wong; Michael Boivin; Penny Holding; Betsy Kammerer; Annelies Van Rie; Prudence Ive; Avindra Nath; Kathy Lawler; Clement Adebamowo; Walter Royal; Jeymohan Joseph Journal: J Neurovirol Date: 2010-05 Impact factor: 2.643
Authors: S Janssen; M A M Huson; S Bélard; S Stolp; N Kapata; M Bates; M van Vugt; M P Grobusch Journal: Infection Date: 2013-12-06 Impact factor: 3.553
Authors: Heena Brahmbhatt; Michael Boivin; Victor Ssempijja; Joseph Kagaayi; Godfrey Kigozi; David Serwadda; Avy Violari; Ronald H Gray Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731
Authors: Itziar Familiar; Shalean M Collins; Alla Sikorskii; Horacio Ruisenor-Escudero; Barnabas Natamba; Paul Bangirana; Elizabeth M Widen; Daniel Achidri; Harriet Achola; Daniel Onen; Michael Boivin; Sera L Young Journal: J Acquir Immune Defic Syndr Date: 2018-03-01 Impact factor: 3.731
Authors: Sumona Chaudhury; Gloria K Mayondi; Paige L Williams; Jean Leidner; Roger Shapiro; Modiegi Diseko; Gbolahan Ajibola; Penny Holding; Vicki Tepper; Joseph Makhema; Chipo Petlo; George R Seage; Shahin Lockman; Betsy Kammerer Journal: AIDS Date: 2018-06-01 Impact factor: 4.177
Authors: Nicole Phillips; Taryn Amos; Caroline Kuo; Jacqueline Hoare; Jonathan Ipser; Kevin G F Thomas; Dan J Stein Journal: Pediatrics Date: 2016-10-11 Impact factor: 7.124
Authors: Michael J Boivin; Linda Barlow-Mosha; Miriam C Chernoff; Barbara Laughton; Bonnie Zimmer; Celeste Joyce; Mutsa Bwakura-Dangarembizi; Mmule Ratswana; Nasreen Abrahams; Lee Fairlie; Hermien Gous; Portia Kamthunzi; Katie McCarthy; Itziar Familiar-Lopez; Patrick Jean-Phillippe; Joan Coetzee; Avy Violari; Mark F Cotton; Paul E Palumbo Journal: AIDS Date: 2018-01-14 Impact factor: 4.177